The samples CLA and CLD recorded 66.16, respectively, 66.89% viability, showing the most evident antitumor activity on Hep-2 tumor cells (Table 3), for the tested concentration (100 μg/disc). The gene discussed is SLC26A3; the disease is neoplasm.